Peptidic Activators Targeting PKG Switch Helix

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Direct pharmaceutical targeting of cGMP-dependent protein kinase (PKG) Iα has been unsuccessful due to its complex, multi-domain architecture, hindering the development of effective therapeutic and diagnostic reagents for vascular diseases.

Innovation Solution

The identification of a unique helical domain, termed the Switch helix (SW), which stabilizes a dimer interface between protomers, allowing for the development of cGMP-independent PKG activators that modulate vasodilation by interacting with the regulatory/catalytic domain, providing a new class of PKG activators.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If direct pharmaceutical targeting of PKG Iα is attempted, then therapeutic potential for vascular diseases is achieved, but the complex multi-domain architecture of PKG hinders successful drug development

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidenzyme architecture complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the PKG enzyme into distinct functional domains, specifically targeting the regulatory domain (residues 78-355) separately from the catalytic domain. This segmentation allows drugs to target specific functional regions rather than attempting to interact with the entire complex multi-domain architecture, thereby overcoming the complexity barrier while maintaining therapeutic effectiveness.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention extracts and isolates the regulatory domain of PKG Iα as a separate targetable entity. By focusing pharmaceutical intervention on this specific extracted domain rather than the complete enzyme, the patent simplifies the drug-target interaction while preserving the ability to modulate overall PKG activity for treating vascular diseases.

Inventive Principle:

Principle #2Taking out (Extraction)

2Ease of operation

If cGMP-dependent activation pathway is used, then PKG activation is achieved, but reliance on cGMP limits therapeutic options and requires indirect activation mechanisms

Engineering Contradiction:

Improveactivation mechanism simplicityVSAvoidtherapeutic pathway flexibility

Core Design Contradiction:

Ease of operationVSAdaptability or versatility

Solution Approach 1:

The patent introduces peptidic compounds as intermediary substances that directly activate the regulatory domain of PKG Iα without requiring cGMP as an intermediate. These peptidic activators serve as direct mediators between the therapeutic agent and the kinase, bypassing the traditional cGMP-dependent pathway and enabling more versatile and direct therapeutic intervention.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS9260486B2Peptidic activators of type I cGMP dependent protein kinases and uses thereof

Publication Date: 2016.02.16 UNIVERSITY OF VERMONT

AI summary

The present invention relates to cGMP protein kinase (PKG) and regulatory domains and methods of use thereof. The structural determination of PKG domains is also described. cGMP independent PKG activators and uses thereof are also described.